When analyzing the composite MACE components separately, GLP-1 receptor agonists were responsible for a reduction in cardiovascular mortality, fatal or non-fatal myocardial infarctions, and fatal or non-fatal strokes, as well as an 11% decreased risk for heart failure hospitalization and a 12% decreased risk of death from any cause (p < 0.001) [102]. The gene discussed is GLP1R; the disease is myocardial infarction.